Chengcheng Huang, Yuxiang Liang, Yang Li, Quan Wei, Liang Ouyang, Jifa Zhang. The epigenetic landscape of rheumatoid arthritis: Pathogenesis and drug therapeutic potentialsJ. Acta Pharmaceutica Sinica B, 2025, 15(11): 5601-5631. DOI: 10.1016/j.apsb.2025.08.022
Citation: Chengcheng Huang, Yuxiang Liang, Yang Li, Quan Wei, Liang Ouyang, Jifa Zhang. The epigenetic landscape of rheumatoid arthritis: Pathogenesis and drug therapeutic potentialsJ. Acta Pharmaceutica Sinica B, 2025, 15(11): 5601-5631. DOI: 10.1016/j.apsb.2025.08.022

The epigenetic landscape of rheumatoid arthritis: Pathogenesis and drug therapeutic potentials

  • Rheumatoid arthritis (RA) represents a persistent autoimmune condition distinguished by a multifaceted etiology that encompasses both genetic and environmental factors. Recent progress in understanding the mechanisms behind RA pathogenesis has delved into the critical role of epigenetic regulatory processes, including DNA methylation, histone modifications, and the regulation by microRNAs (miRNAs). These findings provide new insights into the intricate nature of RA and pave the way for innovative therapeutic strategies. This review consolidates the latest developments in the epigenetic regulation of RA, concentrating on how these mechanisms affect the dysregulated signaling pathways associated with the disease. We analyze the roles of specific proteins that function as ‘writers’, ‘erasers’, and ‘readers’ in epigenetic modifications, highlighting their potential as targets for therapeutic intervention. Additionally, in view of the significance of miRNAs in the pathogenesis of RA, we deliberate on their involvement in disease progression and explore miRNA-based treatment strategies. By integrating these diverse epigenetic dimensions, this review offers a comprehensive epigenetic perspective on RA pathogenesis and identifies promising avenues for future research and therapeutic interventions.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return